Clinical TrialJun 5, 2026, 08:52 AM
NRx Pharma: IV Ketamine Shows Higher Remission vs. Esketamine in RWE Study
AI Summary
NRx Pharmaceuticals announced the presentation of a peer-reviewed poster at the 2026 American Society of Clinical Psychopharmacology conference, detailing Real World Evidence (RWE) on the effectiveness of intravenous (IV) ketamine versus intranasal esketamine for depression. The retrospective study of 8,224 IV ketamine and 1,830 intranasal esketamine patients found significantly higher rates of remission and response for IV ketamine. NRx Pharmaceuticals, which is developing NRX-100 (IV ketamine), noted the increasing emphasis on RWE for drug approvals by regulatory bodies.
Key Highlights
- IV ketamine showed 50% higher remission rates (OR 1.51; P<.001) compared to intranasal esketamine.
- IV ketamine showed 22% higher response rates (OR 1.22; P<.003) compared to intranasal esketamine.
- 34% of IV ketamine patients achieved remission, versus 26% for intranasal S-ketamine patients.
- 63% of IV ketamine patients demonstrated response, versus 58% for intranasal S-ketamine patients.
- Study analyzed 8,224 IV ketamine and 1,830 intranasal esketamine patients from 800 clinics.
- Real World Evidence for depression drug approval is emphasized by recent White House and Congressional actions.
- NRx Pharmaceuticals is developing NRX-100 (preservative-free intravenous ketamine).
Price Impact
More from NRXP